国: カナダ
言語: 英語
ソース: Health Canada
DIGOXIN
PHARMASCIENCE INC
C01AA05
DIGOXIN
0.05MG
SOLUTION
DIGOXIN 0.05MG
ORAL
115ML
Prescription
CARDIOTONIC AGENTS
Active ingredient group (AIG) number: 0107281001; AHFS:
APPROVED
2010-11-10
_ _ _pms-DIGOXIN (digoxin) _ _Page 1 of 51_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-DIGOXIN Digoxin Tablets Tablets, 0.0625 mg, 0.125 mg and 0.25 mg, Oral C.S.D. Digoxin Oral Solution Solution, 0.05 mg/mL, Oral C.S.D. Cardiotonic Glycoside PHARMASCIENCE INC. 6111 Royalmount Avenue, Suite 100 Montréal, QC, Canada H4P 2T4 Date of Initial Authorization: NOV 23, 2022 Submission Control Number: 268869 _ _ _pms-DIGOXIN (digoxin) _ _Page 2 of 51_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 6 4.4 Administration ....................................................................................................... 10 4.5 Missed Dose .......................................................................................................... 10 5 OVERDOSAGE .. 完全なドキュメントを読む